Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects

AIM: Anacetrapib is currently being developed for the treatment of dyslipidaemia. Since warfarin, an anticoagulant with a narrow therapeutic index, is expected to be commonly prescribed in this population, a drug interaction study was conducted. METHODS: In a randomized, open-label, two-period fixed...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Krishna, Rajesh, Stypinski, Daria, Ali, Melissa, Garg, Amit, Cote, Josee, Maes, Andrea, DeGroot, Bruce, Liu, Yang, Li, Susie, Connolly, Sandra M, Wagner, John A, Stoch, S Aubrey
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Science Inc 2012
Témata:
Drug Interactions
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3394135/
https://ncbi.nlm.nih.gov/pubmed/22243494
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2012.04171.x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky